See more : Elco Ltd. (ELCO.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Intra-Cellular Therapies, Inc. (ITCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intra-Cellular Therapies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Dundee Precious Metals Inc. (DPMLF) Income Statement Analysis – Financial Results
- Landcadia Holdings IV, Inc. (LCAHW) Income Statement Analysis – Financial Results
- SoFi Technologies, Inc. (SOFI) Income Statement Analysis – Financial Results
- PT Rimo International Lestari Tbk (RIMO.JK) Income Statement Analysis – Financial Results
- Vuzix Corporation (0LRL.L) Income Statement Analysis – Financial Results
Intra-Cellular Therapies, Inc. (ITCI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.37M | 249.13M | 81.71M | 22.53M | 60.61K | 0.00 | 245.84K | 330.70K | 91.36K | 577.30K | 2.74M | 3.12M |
| Cost of Revenue | 33.75M | 20.44M | 8.03M | 1.90M | 477.12K | 368.67K | 79.42M | 93.83M | 139.63K | 21.23M | 23.03M | 15.49M |
| Gross Profit | 430.63M | 228.69M | 73.67M | 20.64M | -416.51K | -368.67K | -79.17M | -93.50M | -48.26K | -20.65M | -20.29M | -12.37M |
| Gross Profit Ratio | 92.73% | 91.79% | 90.17% | 91.59% | -687.16% | 0.00% | -32,205.56% | -28,273.44% | -52.82% | -3,576.82% | -741.34% | -396.68% |
| Research & Development | 180.14M | 134.72M | 88.85M | 65.78M | 89.12M | 132.17M | 79.42M | 93.83M | 87.72M | 21.23M | 23.03M | 15.49M |
| General & Administrative | 317.66M | 272.98M | 190.11M | 150.06M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Selling & Marketing | 92.20M | 85.80M | 82.50M | 36.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 409.86M | 358.78M | 272.61M | 186.36M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Other Expenses | 0.00 | -1.18M | -2.10M | -282.23K | 0.00 | 0.00 | -245.84K | -330.70K | -60.71K | -29.76K | 0.00 | 0.00 |
| Operating Expenses | 590.01M | 492.32M | 359.36M | 251.86M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Cost & Expenses | 623.75M | 512.76M | 367.40M | 253.76M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Interest Income | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.94M | 1.02M | 303.94K | 29.62K | 39.00K |
| Interest Expense | 0.00 | 7.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.78K | 0.00 | 7.07K | 612.96K | 193.50K |
| Depreciation & Amortization | 528.00K | 656.00K | 533.36K | 528.12K | 477.12K | 368.67K | 213.87K | 196.87K | 139.63K | 25.48K | 23.25K | 47.75K |
| EBITDA | -158.85M | -262.97M | -285.16M | -230.70M | -153.53M | -161.90M | -102.63M | -115.13M | -104.65M | -30.66M | -26.21M | -16.32M |
| EBITDA Ratio | -34.21% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -40,203.17% | -34,872.43% | -115,815.85% | -5,314.87% | -957.76% | -523.31% |
| Operating Income | -159.38M | -263.63M | -285.69M | -231.23M | -154.01M | -162.27M | -102.84M | -118.26M | -105.81M | -30.99M | -26.27M | -16.40M |
| Operating Income Ratio | -34.32% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -41,832.65% | -35,759.96% | -115,815.85% | -5,367.52% | -959.69% | -526.09% |
| Total Other Income/Expenses | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.90M | 1.02M | 296.86K | -583.35K | -154.50K |
| Income Before Tax | -139.04M | -256.25M | -284.12M | -226.99M | -147.72M | -155.13M | -98.83M | -115.36M | -104.79M | -30.69M | -26.85M | -16.56M |
| Income Before Tax Ratio | -29.94% | -102.86% | -347.73% | -1,007.48% | -243,711.05% | 0.00% | -40,203.17% | -34,883.55% | -114,696.75% | -5,316.09% | -981.01% | -531.04% |
| Income Tax Expense | 636.00K | 6.00K | 5.63K | 13.51K | 1.60K | 1.60K | -1.06M | 1.07M | 1.60K | 1.60K | 18.00K | 32.92K |
| Net Income | -139.67M | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M | -97.77M | -116.43M | -104.79M | -30.69M | -26.87M | -16.59M |
| Net Income Ratio | -30.08% | -102.86% | -347.73% | -1,007.54% | -243,713.69% | 0.00% | -39,771.64% | -35,205.79% | -114,698.50% | -5,316.37% | -981.67% | -532.10% |
| EPS | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| EPS Diluted | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| Weighted Avg Shares Out | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.01M | 28.65M | 17.22M | 22.16M |
| Weighted Avg Shares Out (Dil) | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.07M | 28.65M | 17.26M | 22.16M |
Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?
Why Intra-Cellular Therapies Climbed Tuesday
Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted
Source: https://incomestatements.info
Category: Stock Reports